EU Panel Backs Risankizumab (Skyrizi) for Plaque Psoriasis

Share this post

The interleukin-23 inhibitor is for treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
International Approvals

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply